If living with severe hyperhidrosis feels like a constant, exhausting battle against soaked clothing, ruined documents, and hesitant handshakes, you are far from alone. For millions of people, excessive sweating isn’t just a minor cosmetic annoyance—it is a chronic medical condition that disrupts work performance, social choices, and emotional well-being. While many patients manage mild symptoms with clinical antiperspirants or prescription creams, severe primary hyperhidrosis often demands a more durable solution. When non-surgical measures no longer provide relief, surgical intervention offers a reliable path back to everyday confidence. Why Hyperhidrosis Occurs: The Mechanism Behind the Sweat At its core, primary hyperhidrosis isn’t a problem with your sweat glands themselves—histologically, the glands are completely normal. Instead, the condition stems from a dysregulation within the sympathetic nervous system, the body’s involuntary control centre for automatic responses like heart rate and temperature control. Normally, your brain sends signals through these nerve pathways to produce sweat only when you need to cool down, such as during exercise or in high heat. In individuals with hyperhidrosis, these nerve signals become chronically hyperactive or overly sensitive, continuously flooding normal eccrine sweat glands with instructions to produce moisture—even when you are resting in a cool room or completely calm. Research also points to a strong genetic predisposition, with up to 60–65% of patients having a family history of the condition, suggesting that some people simply inherit a nervous system with an over-eager “thermostat”. Understanding the Root Cause: Overactive Nerves To understand how surgery helps, it helps to understand why hyperhidrosis happens in the first place. Primary hyperhidrosis is caused by an overactive sympathetic nervous system—the network responsible for our body’s automatic “fight-or-flight” responses. In a typical response, your body signals sweat glands to cool you down during exercise or heat. In hyperhidrosis, these nerve pathways act like a thermostat stuck on maximum output, continually signalling sweat glands to produce fluid even when you are cold, calm, or completely at rest. The most common surgical approach for severe hyperhidrosis is Endoscopic Thoracic Sympathectomy (ETS). This procedure specifically targets the thoracic sympathetic chain—a slender nerve track running along the spine inside the chest cavity. By identifying and carefully interrupting or clipping the specific nerve segment responsible for driving sweat production in the hands or underarms, surgeons can effectively turn off the faulty signal loop at its source. What to Expect Before, During, and After Surgery Preparing for the Procedure Your journey begins with a comprehensive consultation. Your specialist will evaluate your medical history, review previous non-surgical treatments you’ve tried, and determine if ETS is the right choice for your specific symptoms. Because ETS is most successful for palmar (hand) and axillary (underarm) hyperhidrosis, setting clear expectations about your primary focus areas is a crucial first step. The Surgical Technique ETS is performed under general anaesthesia using minimally invasive keyhole techniques. across the nerve fibres. Because the incisions are so small, muscle damage is minimal, which helps keep post-procedure discomfort low. Immediate Recovery and Healing One of the most remarkable aspects of ETS is how quickly it works: most patients wake up in the recovery room with dry, warm hands immediately. Because ETS is typically an outpatient procedure, you will usually go home the same day once the anaesthesia wears off. You can expect mild soreness in the chest or underarm area for a few days, but most patients are able to return to desk work and routine daily activities within 3 to 5 days. Key Considerations: Weighing the Benefits and Side Effects While ETS boasts high success rates—particularly for palmar hyperhidrosis, where satisfaction rates consistently exceed 90%—it is essential to approach any surgery with a clear understanding of potential trade-offs. The primary consideration discussed during pre-op consultations is compensatory sweating. Because the body’s overall cooling mechanism is adjusted, it may compensate by increasing sweat production in untreated areas, such as the lower back, torso, or thighs. For the vast majority of patients, compensatory sweating is mild to moderate and considered a very acceptable trade-off for dry hands and underarms. However, having a candid discussion with your surgeon ensures you make an informed decision tailored to your lifestyle. Taking the step toward surgery is a personal decision, but you don’t have to navigate it alone. Consulting with an experienced thoracic or vascular specialist can clarify whether ETS is the key to getting your comfort and freedom back. Frequently Asked Questions What is Endoscopic Thoracic Sympathectomy (ETS)? ETS is a minimally invasive surgery that treats severe primary hyperhidrosis, particularly of the hands (palmar) and armpits (axillary). Through tiny incisions hidden under the armpit, the surgeon uses a miniature camera to locate and interrupt the specific sympathetic nerve chain responsible for sending overactive sweat signals. Am I a candidate for hyperhidrosis surgery? Good candidates are generally individuals who experience severe, life-disrupting sweating in localized areas—especially the palms—and have not had success with topical treatments, oral medications, or Botox. Your surgeon will review your medical history to ensure surgical intervention is appropriate for your specific type of hyperhidrosis. How fast are the results? Results for palmar hyperhidrosis are typically immediate. Patients usually notice warm, dry hands as soon as they wake up from anaesthesia in the recovery room. What is the recovery time? Because ETS uses keyhole incisions, recovery is relatively fast. Most people go home the same day and can resume normal daily activities and light routines within a few days. You may feel mild soreness in your chest or underarms for a short period. What is compensatory sweating? Compensatory sweating is the most common side effect of ETS surgery, where the body begins sweating in new, untreated areas—such as the lower back, chest, or thighs—to make up for the reduced sweating elsewhere. For most patients, it is mild and manageable, but it is an important factor to discuss thoroughly with your surgeon before deciding on treatment. Are the results permanent? Yes, cutting or cauterizing the sympathetic nerve chain creates a permanent interruption in the sweat signal path. In cases where

What is a Pneumothorax? A pneumothorax is the medical term for a collapsed lung. Under normal conditions, your lungs fill up the chest cavity like two balloons inside a box. Between your lungs and your ribs is a tiny space called the pleural space. If air somehow sneaks into this space, it presses against the outside of your lung. That external pressure makes it hard for the lung to expand, causing part—or all—of it to deflate or collapse. The Two Main Types of Spontaneous Collapsed Lungs When a lung collapses without an obvious injury (like a car accident or broken rib), doctors call it “spontaneous.” This usually falls into one of two categories: How Is a Collapsed Lung Treated? The main goal of treatment is simple: get the trapped air out of your chest so your lung can re-expand and prevent it from happening again. Depending on how much air is trapped and how you feel, your care plan will usually follow one of three approaches: 1.   Simple Observation and Oxygen Therapy 2.   Draining the Air (Needle Aspiration or Chest Tube) 3.   Surgical Repair (VATS s Pleurodesis) If a chest tube doesn’t stop the leak, or if this is the second time your lung has collapsed, surgery is usually recommended to fix the root cause. Today, almost all of these operations are done using Keyhole Surgery (VATS), which uses tiny incisions (sometimes just a single small cut). This means significantly less pain, tiny scars, and a much faster return to your normal life compared to older open-chest surgeries. Frequently Asked Questions (FAQs) What does a collapsed lung feel like? The two hallmark symptoms are sudden, sharp chest pain (often worse when taking a deep breath) and sudden shortness of breath. The pain can sometimes radiate to your shoulder or back. If you experience these symptoms, seek emergency medical care immediately. What is a “tension pneumothorax”? This is a medical emergency. It happens when trapped air gets stuck in a “one-way valve” loop—air goes into the chest space every time you inhale, but none gets out when you exhale. Pressure builds up rapidly, squishing the collapsed lung and putting dangerous pressure on your heart. Doctors treat this immediately on the spot by relieving the pressure with a needle or tube. If my lung collapses once, will it happen again? What should I avoid after having a collapsed lung?

Introduction Pleural empyema—the collection of frank pus within the pleural cavity—represents an advanced and dangerous stage of pleural infection. While often originating as a complication of community- acquired or hospital-acquired pneumonia (parapneumonic effusion), empyema can also develop secondary to thoracic trauma, surgical procedures, esophageal perforation, or subdiaphragmatic abscesses. Left untreated or inadequately managed, empyema transitions from a fluid-based inflammatory collection to a rigid, fibrous process that traps the lung, compromises respiratory mechanics, and leads to persistent systemic sepsis. Understanding the stage of the disease is crucial, as timing directly dictates whether conservative management will suffice or if advanced surgical intervention is required. Staging and Pathophysiology The American Thoracic Society classifies pleural empyema into three distinct, progressive stages:   Stage   Name Key Characteristics Preferred Management Strategy   Stage 1   Exudative Phase Thin, clear fluid accumulates; low cellular content; lung expands fully. Antibiotics + Tube Thoracostomy (Chest Drain)     Stage 2     Fibrinopurulent Phase Pus develops; heavy fibrin deposition forms septations and “loculations” (pockets). Image-guided drainage, intrapleural fibrinolytics, or early VATS     Stage 3     Organizational Phase Dense fibrous tissue forms a thick “peel” over the visceral pleura, trapping the lung.   Surgical Decortication (VATS or Open Thoracotomy) Therapeutic Treatment Pathways Effective management of empyema relies on two fundamental principles: controlling the source of infection through targeted antimicrobial therapy and achieving complete pleural space source control (evacuating pus and allowing the lung to fully re-expand). 1.  Broad-Spectrum Antimicrobial Therapy Empiric intravenous antibiotics must be initiated immediately upon suspicion, later tailored based on pleural fluid cultures and sensitivities. Because pleural fluid penetration varies, regimens usually cover common respiratory pathogens, including anaerobes, Streptococcus pneumoniae, Staphylococcus aureus (including MRSA), and Gram-negative bacilli. 2.  Tube Thoracostomy s Intrapleural Fibrinolysis recombinant DNase directly into the chest tube can help break down fibrin webs and viscous pus, potentially avoiding surgery in select high-risk patients. Surgical Interventions for Empyema When medical management and simple chest tube drainage fail to clear the infection or re-expand the lung, thoracic surgery becomes mandatory. Surgical Goals Surgical Techniques VATS Decortication Modern thoracic practice heavily favors minimally invasive VATS (or Uniportal VATS). Through small ports, the surgeon utilizes specialized instruments to scrape away the thick fibrin peel from both the visceral pleura (lung surface) and parietal pleura (chest wall surface). Open Decortication In cases where chronic inflammation has created dense, vascularized tissue that risks massive bleeding or pulmonary tearing during VATS, converting to an open thoracotomy ensures patient safety and complete surgical clearance. Postoperative Management and Recovery Following surgical decortication, patients are typically monitored in a specialized thoracic ward or step-down unit. tubes remain in place connected to continuous low suction (−10 to −20 cmH2O) to drain lingering fluid and ensure the lung stays fully expanded against the chest wall. clinical resolution and inflammatory markers (CRP and white blood cell count). Frequently Asked Questions (FAQs) What is the main difference between a parapneumonic effusion and an empyema? A parapneumonic effusion is any fluid accumulation in the pleural space that occurs secondary to pneumonia. Initially, this fluid is sterile and clear (uncomplicated). If bacteria migrate into this fluid, it becomes complicated. When the pleural fluid contains visible pus, has a foul odor, or tests positive for bacteria on Gram stain or culture, it is formally defined as an empyema. Why can’t empyema be treated with antibiotics alone? Antibiotics alone are rarely effective for empyema because infected pleural fluid becomes thick, acidic, and compartmentalized by fibrin walls. This localized environment impairs antibiotic penetration and neutralizes white blood cell activity. Without physical drainage or surgical removal of the pus (“source control”), the infection will persist. When is surgery necessary for empyema? Surgery is indicated when: What are the risks of delaying surgery for a trapped lung? Delaying surgical intervention allows the fibrous peel covering the lung to become increasingly rigid and vascularized. This can lead to permanent loss of lung volume, chronic fibrothorax, chest wall deformity, persistent systemic infection, or the formation of a bronchopleural fistula (an abnormal passage between the lung’s airways and the pleural space). How long is the recovery period after VATS decortication? Hospital stays after VATS decortication typically range from 4 to 7 days, largely depending on how quickly the lung re-expands and chest tube drainage subsides. Most patients can return to light daily activities within 2 to 3 weeks, though full energy recovery and return to vigorous physical activity or work may take 4 to 6 weeks.

What is VATS Lobectomy? Imagine needing a major lung operation but not requiring the long, muscle-dividing incision that patients once associated with chest surgery. That is exactly what Video-Assisted Thoracoscopic Surgery (VATS) lobectomy has made possible. Over the last two decades, VATS has transformed thoracic surgery by allowing surgeons to remove an entire lobe of the lung through a few small incisions using a high-definition camera and specially designed instruments. Today, this minimally invasive technique has become the preferred approach for many patients with early-stage lung cancer, offering the same cancer operation while significantly reducing the physical trauma of surgery. Major international guidelines now recommend minimally invasive surgery over traditional thoracotomy whenever technically feasible for patients with Stage I non-small cell lung cancer. (chestnet.org) A lobectomy refers to the removal of one of the five lobes of the lungs. The right lung contains three lobes, while the left lung contains two. Removing the affected lobe completely, along with its associated lymph nodes, remains the gold standard treatment for most operable early-stage lung cancers because it provides the best balance between complete tumour removal and long-term survival. Unlike a wedge resection, which removes only a small portion of the lung, or a segmentectomy, which removes a specific anatomical segment, a lobectomy removes the entire diseased lobe while preserving the remaining healthy lung. This approach minimizes the risk of leaving behind microscopic disease and has consistently demonstrated excellent long-term cancer control in appropriately selected patients. (chestnet.org) For patients, the biggest difference lies in the experience after surgery. Instead of a large incision and significant rib spreading, VATS generally involves two to four small incisions, often between 1 and 4 cm in length. The camera provides a magnified view of delicate structures such as the pulmonary artery, pulmonary veins, bronchus, lymph nodes, and surrounding nerves, enabling meticulous dissection while minimizing tissue injury. Patients frequently experience less postoperative pain, require fewer opioid medications, recover lung function more quickly, and return to daily life sooner than those undergoing conventional open surgery. These advantages have made VATS one of the most important advances in modern thoracic surgery. Why VATS Lobectomy Has Become the Preferred Treatment for Early Lung Cancer Only a generation ago, almost every lung cancer operation required a thoracotomy, involving a long incision across the chest with the ribs spread apart to reach the lung. Although thoracotomy remains an essential operation in selected complex cases, advances in imaging, instrumentation, anaesthesia, and surgical expertise have shifted the standard of care toward minimally invasive techniques. Today, VATS lobectomy is considered the preferred surgical approach for most patients with resectable early-stage non-small cell lung cancer because it combines excellent oncological outcomes with a substantially easier postoperative recovery. International guidelines from the American College of Chest Physicians recommend minimally invasive approaches over thoracotomy for clinical Stage I disease whenever appropriate. (chestnet.org) One of the major concerns when VATS was first introduced was whether smaller incisions might compromise cancer treatment. Surgeons questioned whether lymph node dissection would be adequate, whether tumour handling might be inferior, and whether long-term survival could suffer. Those concerns have now been addressed by extensive clinical research. Recent analyses, including an individual patient data meta-analysis of randomized trials published in The Lancet, demonstrate that VATS provides oncological outcomes equivalent to open lobectomy while preserving its well-recognized benefits of reduced pain, fewer postoperative complications, faster recovery, and improved quality of life. (PubMed) Patients with reduced lung reserve particularly benefit from VATS. Individuals with chronic obstructive pulmonary disease (COPD), previous smoking-related lung damage, advanced age, or multiple medical conditions often tolerate minimally invasive surgery better because postoperative breathing mechanics recover more rapidly. Smaller incisions facilitate earlier mobilisation, effective coughing, improved physiotherapy participation, and reduced pulmonary complications such as pneumonia. Enhanced Recovery After Surgery (ERAS) pathways now strongly recommend minimally invasive pulmonary resection whenever feasible because these advantages translate into shorter hospital stays and improved patient outcomes. (OUP Academic) The increasing adoption of VATS also reflects improvements in surgical training and technology. High-definition 4K imaging systems, advanced energy devices, articulating staplers, and sophisticated anaesthetic techniques allow experienced thoracic surgeons to perform increasingly complex resections safely through small incisions. While not every patient is suitable for VATS, and conversion to open surgery remains necessary in selected situations for safety, the vast majority of appropriately selected early-stage lung cancer patients can now undergo definitive treatment through a minimally invasive approach. Who Needs a VATS Lobectomy? One of the most common misconceptions is that VATS lobectomy is performed only for lung cancer. Although early-stage non-small cell lung cancer remains the most frequent indication, modern thoracic surgeons use VATS lobectomy for a much broader range of carefully selected conditions. The decision is never based solely on the diagnosis; it also depends on tumour size, location, lymph node involvement, previous infections, overall lung function, and the patient’s ability to tolerate surgery. Every case requires individualized evaluation using high-resolution CT scanning, PET-CT where appropriate, pulmonary function testing, and multidisciplinary discussion. Lung Cancer The ideal candidate is a patient with Stage I or selected Stage II non-small cell lung cancer in whom the tumour is confined to a single lobe without extensive invasion of major blood vessels or adjacent organs. These patients often achieve the greatest benefit from minimally invasive surgery because complete cancer removal can be combined with a faster recovery and earlier return to normal life. Even after neoadjuvant therapy, selected patients may still be candidates for VATS in experienced centres. Benign Lung Diseases Not every lobectomy is performed for cancer. Certain non-cancerous diseases permanently destroy lung tissue, making surgical removal the best long-term solution. Examples include severe bronchiectasis, destroyed lung following tuberculosis, chronic lung abscesses, localized fungal infections such as aspergilloma, congenital abnormalities including congenital pulmonary airway malformation (CPAM), and symptomatic giant bullae. In these situations, removing the diseased lobe can eliminate recurrent infections, persistent cough, haemoptysis, or chronic breathlessness while preserving the remaining healthy lung. Metastatic Lung Tumours Although pulmonary metastases are usually treated with limited resections, carefully selected patients

“Tuberculosis is curable, but cure does not always mean that the lungs return to normal”. This distinction is one of the most important things I explain to patients who come to the thoracic surgery clinic months or even years after completing tuberculosis treatment. Their sputum tests may be negative. Their anti-tubercular medicines may have ended long ago. Yet they may still be coughing every day, producing large amounts of sputum, suffering repeated chest infections, becoming breathless with ordinary activity, or suddenly coughing up blood, which brings us to the question “when is surgery needed after TB” Why does this happen? Think of pulmonary tuberculosis as a fire inside a house. Antibiotics can extinguish the fire, but they cannot always rebuild the rooms damaged by it. In the lungs, healed tuberculosis may leave behind cavities, fibrosis, distorted bronchi, bronchiectasis, pleural thickening, calcification, fungal infection, or even destruction of an entire lobe or lung. These structural changes are increasingly recognised under the broad concept of post-tuberculosis lung disease, or PTLD. The important question is not simply, “Did you have TB?” The more useful question is: “What damage has TB left behind, and is that damage now causing a problem that cannot be controlled without surgery?” Most people who have recovered from tuberculosis do not need an operation. Surgery is reserved for carefully selected situations in which a damaged portion of the lung has become a persistent source of bleeding, infection, fungal disease, pus, or major functional problems. The decision requires careful evaluation because surgery after TB can be technically more demanding than routine lung surgery. This article explains when surgery is needed after TB, what symptoms should raise concern, what tests are required before surgery, and which operations may be considered. TB May Be Cured, but the Lung May Remain Damaged Tuberculosis is one of the most important infectious diseases worldwide, and the scale of the problem remains enormous. According to the latest global estimates, approximately 10.7 million people developed TB in 2024. As treatment and survival improve, another challenge becomes increasingly visible: what happens to the lungs after microbiological cure? A patient may complete treatment successfully but be left with permanent structural changes. These can include scarring, lung volume loss, thickened pleura, cavities, airway distortion, bronchiectasis, and areas of severely damaged or non-functioning lung. Some people remain almost completely asymptomatic. Others develop chronic respiratory problems that significantly affect quality of life. The pattern varies greatly from patient to patient. One person may have a small scar visible only on a CT scan. Another may have severe upper-lobe bronchiectasis causing daily production of infected sputum. A third may develop an aspergilloma inside an old TB cavity and present with recurrent haemoptysis. At the extreme end of the spectrum, an entire lung may become shrunken, fibrotic, bronchiectatic, and chronically infected—a condition commonly called a post-TB destroyed lung. This is why treatment after TB cannot be based on the chest X-ray alone. A frightening-looking scan does not automatically mean that surgery is necessary, while a relatively localised abnormality may require intervention if it repeatedly causes dangerous bleeding. Understanding Post-Tuberculosis Lung Disease Post-tuberculosis lung disease is a broad term describing chronic respiratory abnormalities attributable, at least partly, to previous pulmonary TB. Modern respiratory literature increasingly emphasises that the end of anti-tubercular treatment should not necessarily be the end of clinical assessment, especially when symptoms continue. PTLD can produce different combinations of obstructive lung disease, restrictive impairment, bronchiectasis, cavitation, fibrosis, pleural disease, pulmonary vascular problems, and secondary infections. This diversity explains why there is no single treatment called “post-TB surgery.” The surgeon does not operate on the history of tuberculosis itself; the operation is directed at a specific structural complication. For example, a patient with diffuse bilateral fibrosis and breathlessness will usually not benefit from removal of one area of lung. Such a patient may need pulmonary rehabilitation, inhaled treatment where indicated, vaccination, nutritional support, airway-clearance strategies, and specialist respiratory care. In contrast, a patient with otherwise good lungs but one severely bronchiectatic lobe causing repeated pneumonia may potentially benefit from resection of that localised disease. The central principle is therefore localisation. Surgery works best when the dangerous or symptomatic disease is anatomically identifiable and removable, while the remaining lung has enough reserve to support the patient comfortably. Does Every Patient With Lung Damage After TB Need Surgery? No. In fact, the majority of patients with radiological evidence of previous TB do not need thoracic surgery. A CT scan may show scars, calcification, minor cavities, or limited bronchiectatic changes in someone who feels well and has no repeated infections or bleeding. Operating simply because a scan looks abnormal is rarely sensible. Surgery has a clear role when the expected benefit of removing the diseased area is greater than the risk of the operation and the loss of functioning lung tissue. Before considering surgery, we usually ask several practical questions. Is the patient having recurrent or significant haemoptysis? Are infections occurring repeatedly despite appropriate medical treatment? Is there an aspergilloma inside an old cavity? Is the abnormality confined to one lobe or one lung? Is the affected lung contributing useful respiratory function, or has it become a non-functioning source of sepsis? Can the patient tolerate the proposed operation? These questions matter because post-TB lung surgery is not a cosmetic repair of an abnormal scan. Its purpose is to solve a meaningful clinical problem. The operation may prevent life-threatening bleeding, remove a chronically infected lobe, eliminate a resectable fungal cavity, or deal with a severely destroyed and repeatedly infected lung. The timing of surgery is equally important. Operating during uncontrolled infection, severe malnutrition, or uncertain TB activity may increase risk. Careful preparation—including microbiological assessment, bronchoscopy in selected patients, nutritional optimisation, pulmonary function testing, and precise anatomical mapping—is often as important as the operation itself. The Main Reasons When Surgery May Be Needed After TB There are several recognised situations in which a thoracic surgical opinion becomes particularly important. These conditions often overlap. A patient may simultaneously have